Loading viewer...
investor_presentation
Format: PDF investor_presentation
Corporate Corporate Half-Year Results Presentation 2017 Lonza Delivers Strong Performance in First Half 2017 and Sets a Strong Foundation for Continued Attractive Mid -Term Performance Richard Ridinger –CEO Rodolfo Savitzky –CFO 26 July 2017
Half-Year Results Presentation 2017
Lonza Delivers Strong Performance in First
Half 2017 and Sets a Strong Foundation for
Continued Attractive Mid -Term Performance
Richard Ridinger –CEO
Rodolfo Savitzky –CFO
26 July 2017Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listi ng on the Singapore
Exchange Securities Trading Limited (“SGX -ST”). Lonza Group Ltd is not subject to the SGX -ST’s continuing listing requirements but remains subject to
Rules 217 and 751 of the SGX -ST Listing Manual.
Forward -looking statements contained herein are qualified in their entirety as there are certain factors that could cause result s to differ materially from
those anticipated. Any statements contained herein that are not statements of historical fact (including statements containin g the words “outlook”,
“believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should be considered to be forward -looking s tatements. Investors are
cautioned that all forward -looking statements involve risks and uncertainty. There are a number of important factors that could cause actual results or
events to differ materially from those indicated by such forward -looking statements, including the timing and strength of new pr oduct offerings; pricing
strategies of competitors; the company’s ability to continue to receive adequate products from its vendors on acceptable term s, or at all, and to continue
to obtain sufficient financing to meet its liquidity needs; difficulty to maintain relationships with employees, customers an d other business partners; and
changes in the political, social and regulatory framework in which the company operates, or in economic or technological tren ds or conditions, including
currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. In particular, the assumpt ions underlying Outlook 2017
and Mid -Term Guidance 2022 herein may not prove to be correct. The statements in Outlook 2017 and Mid -Term Guidance 2022 constitute forward -
looking statements and are not guarantees of future financial performance. Lonza’s actual results of operations could deviate materially from those set
forth in Outlook 2017 and Mid -Term Guidance 2022 as a result of the factors described above or other factors. Investors should not place undue reliance
on the statements in Outlook 2017 and Mid-Term Guidance 2022. Except as otherwise required by law, Lonza disclaims any intention or obligation to
update any forward -looking statements as a result of developments occurring after this report was made.
2Additional Information and Disclaimer
Lonza Highlights HY 2017 & Segment Developments
Capsugel Acquisition & Update on Integration
Mid-Term Guidance & Growth Initiatives
Events Calendar & Contact Details
Corporate | 26 July 2017 3Lonza continued strong performance with 15.1% sales and 43.3%
Pharma&Biotech with outstanding results in first half 2017 and
Preview truncated — download the full document for the complete content.
investor_presentation
35 Pages
investor_presentation
27 Pages
Selina